Krystal Biotech, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
Krystal Biotech, Inc. (KRYS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price of $162.08 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-08-03
- Krystal Biotech, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2026-03-31 was $156.67, a 46.41% increase year-over-year.
- Krystal Biotech, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2025-03-31 was $107.01, a 57.62% increase year-over-year.
- Krystal Biotech, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2024-03-31 was $67.89, a 3.51% increase year-over-year.
- Krystal Biotech, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2023-03-31 was $65.59, a 7.10% increase year-over-year.
- Krystal Biotech, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2025 was $109.35, a 38.45% increase from fiscal 2024.
- Krystal Biotech, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2024 was $78.98, a 22.85% increase from fiscal 2023.
- Krystal Biotech, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2023 was $64.29, a 8.56% increase from fiscal 2022.
- Krystal Biotech, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2022 was $59.22, a 3.47% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $162.08 10-Q · filed 2026-08-03 | |||
| 2026-03-31 | $156.67 10-Q · filed 2026-05-04 | |||
| 2025-12-31 | $109.35 10-K · filed 2026-02-17 | |||
| 2025-09-30 | $107.43 10-Q · filed 2025-11-03 | |||
| 2025-06-30 | $105.98 10-Q · filed 2026-08-03 | |||
| 2025-03-31 | $107.01 10-Q · filed 2026-05-04 | |||
| 2024-12-31 | $78.98 10-K · filed 2026-02-17 | |||
| 2024-09-30 | $70.52 10-Q · filed 2025-11-03 | |||
| 2024-06-30 | $68.85 10-Q · filed 2025-08-04 | |||
| 2024-03-31 | $67.89 10-Q · filed 2025-05-06 | |||
| 2023-12-31 | $64.29 10-K · filed 2025-02-19 | |||
| 2023-09-30 | $64.19 10-Q · filed 2024-11-04 | |||
| 2023-06-30 | $63.14 10-Q · filed 2024-08-05 | |||
| 2023-03-31 | $65.59 10-Q · filed 2024-05-06 | |||
| 2022-12-31 | $59.22 10-K · filed 2024-02-26 | |||
| 2022-09-30 | $58.90 10-Q · filed 2022-11-07 | |||
| 2022-06-30 | $55.24 10-Q · filed 2022-08-08 | |||
| 2022-03-31 | $61.24 10-Q · filed 2022-05-09 | |||
| 2021-12-31 | $61.35 10-K · filed 2023-02-27 | |||
| 2021-09-30 | $61.28 10-Q · filed 2021-11-08 | |||
| 2021-06-30 | $53.79 10-Q · filed 2021-08-09 | |||
| 2021-03-31 | $42.43 10-Q · filed 2021-05-10 | |||
| 2020-12-31 | $38.24 10-K · filed 2022-02-28 | |||
| 2020-09-30 | $30.55 10-Q · filed 2020-11-09 | |||
| 2020-06-30 | $21.68 10-Q · filed 2020-08-07 | |||
| 2020-03-31 | $21.28 10-Q · filed 2020-05-04 | |||
| 2019-12-31 | $20.82 10-K · filed 2021-03-01 | |||
| 2019-09-30 | $22.36 10-Q · filed 2019-11-04 | |||
| 2019-06-30 | $19.65 10-Q · filed 2019-08-05 | |||
| 2019-03-31 | $18.71 10-Q · filed 2019-05-07 | |||
| 2018-12-31 | $14.96 10-K · filed 2020-03-10 | |||
| 2018-09-30 | $14.96 10-Q · filed 2018-11-05 | |||
| 2018-06-30 | $10.00 10-Q · filed 2018-08-06 | |||
| 2018-03-31 | $10.00 10-Q · filed 2018-05-07 | |||
| 2017-12-31 | $2.46 10-K · filed 2018-03-12 | |||
| 2017-09-30 | $2.46 10-Q · filed 2017-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |